VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.8650
+0.0302 (3.62%)
Jul 15, 2026, 3:23 PM EDT - Market open
VivoSim Labs Revenue
In the fiscal year ending March 31, 2026, VivoSim Labs had annual revenue of $131.00K, down -9.03%. VivoSim Labs had revenue of $40.00K in the quarter ending March 31, 2026, a decrease of -21.57%.
Revenue (ttm)
$131.00K
Revenue Growth
-9.03%
P/S Ratio
18.45
Revenue / Employee
$9,357
Employees
14
Market Cap
2.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 131.00K | -13.00K | -9.03% |
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVIVS News
- 6 hours ago - Why Is Penny Stock VivoSim Labs (VIVS) Up Today? - TipRanks
- 6 hours ago - VivoSim receives $5M milestone payment from Eli Lilly - TheFly
- 6 hours ago - VivoSim sees FY27 revenue up over 500% - TheFly
- 7 hours ago - VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 - GlobeNewsWire
- 16 days ago - VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting - GlobeNewsWire
- 2 months ago - VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewsWire
- 3 months ago - VivoSim Announces Pricing of up to a $4 Million Public Offering - GlobeNewsWire
- 4 months ago - VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - GlobeNewsWire